Cempra, a biotech developing potent antibiotics to fight pneumonia and skin infections, will see its quiet period end on 3/14/12. On 2/2/12, the company raised $50.4 million by offering 8,400,000 shares at $6.00, below the range of $11.00 to $13.00. Stifel Nicolaus Weisel, Leerink Swann, and Cowen & Company acted as lead managers on the deal.
